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 Diabetics have higher mortality after myocardial infarction (MI), yet little is known regarding the 
impact of quality of care on long-term survival in older post-MI diabetics.  Using data from the 
Cooperative Cardiovascular Project (CCP), a national cohort of 234,769 Medicare patients aged 65 or older 
hospitalized with confirmed AMI between 1994-1995, we assessed differences in 10-year mortality 
outcomes between diabetics and non-diabetics using Cox proportional regression.  To account for quality of 
care, a composite measure among ideal candidates was constructed and entered into the final model 
adjusting for use of aspirin & beta-blocker on admission/discharge, angiotensin-converting enzyme 
inhibitors at discharge, reperfusion within 6 hours of admission, and smoking counseling at discharge.  We 
also assessed the relationship between insulin use, sulfonylureas/biguanides, and statin therapy and long-
term mortality within the diabetic cohort.  
The final study sample included 203,658 cases: 32% were diabetics.  Compared to non-diabetics, 
diabetics were younger (75 vs. 76, p<0.001), female (53% vs. 47%, p<0.001), had more comorbidities, and 
unlikely to receive evidence-based care (59% vs. 64%, p<0.001).  The unadjusted HR for mortality among 
diabetics vs. non-diabetics was 1.38 (95% CI: 1.37-1.40).  After adjusting for demographics, past medical 
history, procedures during hospitalization, medications on admission/discharge, and quality of care, the HR 
was 1.29 (95% CI: 1.27-1.31).  Among diabetics, those on insulin or oral hypoglycemic therapy during the 
initial hospitalization for AMI had the highest risk of mortality during the last 7 years, after adjustment for 
demographics, clinical characteristics, and quality of care (HR insulin=1.30, 95% CI: 1.25-1.35; HR oral 
hypoglycemics=1.11, 95% CI: 1.08-1.15) whereas those on statin therapy were not at increased risk (HR 
statin=0.95, 95% CI: 0.90-1.02).   
As compared to non-diabetics, older diabetics had a 29% increase in mortality even after adjusting 
for demographics, clinical variables during hospitalization, and quality of care (HR=1.29, 95% CI: 1.27-
1.31).  Additionally, within the diabetic cohort, the risk of long-term mortality was highest among those on 
insulin or oral hypoglycemic therapy during initial hospitalization for AMI.  Our study demonstrates that 
neither patient characteristics nor quality of care fully account for the poor outcomes among diabetics 
suggesting that metabolic risk factors associated with diabetes ultimately require therapies beyond those 
currently recommended for post-MI patients. 
                                                 
3 A portion of this abstract was presented at the American Heart Association’s Scientific Sessions, November 2005.  
Publication reference: Marwah Abdalla, Barbara Gulanski, Yun Wang, Edward Havranek, Frederick Masoudi, 
Harlan Krumholz, JoAnne Foody.  “Ten-Year Mortality for Older Diabetics Hospitalized With Acute Myocardial 
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I. Introduction 
Worldwide, cardiovascular disease (CVD) is the leading cause of death (3).  The 
World Health Organization (WHO) estimates that 17 million people die of cardiovascular 
disease annually, of which 7.2 million deaths are attributable to coronary heart disease 
(CHD) alone (1).  In the U.S., CHD is the leading cause of death (Table 1; Figure 2-3).  
In 2002, 1 out of every 5 deaths was attributable to CHD (9).  Of those who die of CHD, 
83% are over the age of 65 (11).  According to the American Heart Association (AHA), 
in the U.S., acute myocardial infarction (AMI), a subset of CHD caused over 175,000 
deaths and led to over $27 billion in healthcare spending in 2002 (9).  Additionally, those 
who have suffered an AMI are more likely to experience sudden cardiac death at a rate 4 





Table 1: Estimated Prevalence and Mortality from Cardiovascular and Coronary Heart 
Disease in the U.S. By Race and Gender-Year 2003.  Source: “The Atlas of Heart 










Figure 1-2: Taken from: “The Atlas of Heart Disease and Stroke” American Heart 
Association, pg 9 (1).   
While traditional risk factors such as smoking, abnormal lipid levels, 
hypertension, abdominal obesity, and lack of physical activity have long been implicated 
in the pathophysiology leading to the development of AMI, diabetes is also a strong risk 
factor for CHD and has even been described by the AHA as a “cardiovascular disease” 
(12).  Worldwide, it is estimated that there are 177 million diabetics and diabetes is now 
the fifth leading cause of death (13).  Currently in the U.S., there are 20.8 million 
diabetics, of whom 5.2 million also have CHD (Figure 3) (5).  While microcomplications 
such as nephropathy, neuropathy, and retinopathy have long been recognized as causes of 
increased morbidity and mortality for diabetics, CHD, and in particular AMI, has now 
become the leading cause of death for diabetics, affecting approximately 55% of patients 
(14, 15).  In fact, of patients hospitalized with AMI, it is estimated that 30% have 
diabetes (16).  Not only are diabetics at a greater risk of developing CHD (17) but once 
they have cardiovascular complications (i.e. myocardial infarction, congestive heart 
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failure (CHF), arrhythmias, or strokes) they have an increased short-term morbidity and 
mortality.   
                                
 
 
Figure 3: Number of Diabetics in Millions (age 35 and older) with Self-Reported 
Cardiovascular Disease (1997-2003) Source: Centers for Disease Control and Prevention 
(CDC) (5)  
Unfortunately, the prevalence of diabetes is increasing steadily especially among 
the elderly (Figure 4; Appendix 1-2) (8).  Additionally, as depicted in Figure 5, among 
diabetics, the elderly also have the highest prevalence of cardiovascular disease.  As the 
population ages the interaction of diabetes and cardiovascular disease will potentially be 
one of the leading public health problems facing the world and efforts to understand and 
combat these diseases will be essential.   
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Figure 4: Prevalence of Diabetes Worldwide by Age and Sex in the Year 2000 
Source: Wild et al., “Global Prevalence of Diabetes: Estimates for the Year 2000 
and Projections for 2030” (Figure 1) (8) 
                    
 Figure 5: Prevalence of any Cardiovascular Disease Among Diabetics by Age (age 
35 and older) (1997-2003: Self-Reported) Source: Centers for Disease Control and 
Prevention (CDC), National Center for Health Statistics, Division of Health 
Interview Statistics, data from the National Health Interview Survey (5). 
 
 
Although this past decade has been instrumental in characterizing some of the 
reasons behind the increased morbidity and short-term mortality of diabetics post-MI and 
while more aggressive secondary prevention efforts have been put in place, diabetics still 
fare worse during hospitalization for MI as compared with non-diabetics.  While much is 
known about short-term mortality in diabetics post-MI, less is known about long-term 
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mortality in this group.  Furthermore, little is known about long-term mortality in older 
patients.  Thus, this thesis will characterize long-term outcomes for older diabetics 
hospitalized with AMI.  It is anticipated that results from this study will advance current 
knowledge about the interaction between diabetes and cardiovascular disease.   
 
Morbidity and Mortality: Increased Risk after an Acute MI 
One area which has been researched extensively has been the impact of diabetes 
on the short-term morbidity and mortality associated with AMI (12, 18-23).  It has been 
shown in several studies that after suffering an AMI, diabetics have worse outcomes 
compared to their non-diabetic counterparts (12, 18-23) although controversy exists 
whether these worse outcomes are related to the increased comorbid conditions diabetics 
have.  For example, Chyun et al. analyzed the medical records of Connecticut Medicare 
beneficiaries aged 65 or older who were 30-day survivors of AMI to determine their risk 
of recurrent MI, CHF, and mortality rates one year post hospital discharge.  Results 
showed that at baseline, compared to non-diabetic patients, diabetics were more likely to 
have comorbid conditions such as CHF, stroke, chronic renal insufficiency, MI, 
peripheral vascular disease and hypertension (p<0.001).  Analysis of 1-year mortality 
rates showed that the unadjusted relative risk of death was highest among diabetics, 
especially non-insulin dependent diabetics (RR=1.55, 95% CI: 1.18-2.03).  However after 
adjusting for comorbid conditions, clinical findings, and myocardial characteristics at 
time of admission, this no longer remained statistically significant (RR=1.08, 95% CI: 
0.82-1.43).  In terms of the risk for developing complications, the study showed that the 
relative risk of readmission for recurrent MI was highest for diabetics.  Furthermore, 
insulin-dependent diabetics were the group most likely to be readmitted for CHF 
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(RR=2.00, 95% CI: 1.40-2.86) (22).  On the other hand, in a retrospective cohort study of 
117,599 Medicare patients hospitalized with AMI, Berger et al. showed that diabetic 
patients had higher 30-day and 1-year mortality rates when compared to non-diabetics 
after adjusting for differences in comorbidities.  Furthermore, among the three different 
subgroups of diabetics (diet-controlled, on oral agents, on insulin), insulin-treated 
diabetics had the highest mortality at 30 days and one year even after adjustment for 
therapeutic interventions, clinical, demographic, and hospital characteristics (OR=1.14, 
95% CI: 1.08-1.20 for 30-day mortality; OR=1.48, 95% CI: 1.41-1.55 for 1-year 
mortality) (24).   
Congestive heart failure, along with increased rates of reinfarction and recurrent 
ischemia, has been noted to be one of the primary causes of the excess in-hospital 
mortality of diabetic patients post-MI (18, 19).  Jaffe et al. found that although diabetic 
patients had an increased incidence of CHF post-MI, they tended to have smaller infarct 
sizes when compared to non-diabetics, suggesting that there are other additional factors 
yet unidentified which may contribute to the excess mortality risk (12, 19, 25-27).  
Although somewhat controversial, some studies have demonstrated that diabetic patients 
have more severe coronary atherosclerosis than non-diabetic patients (18, 28-30), 
suggesting that there are metabolic derangements, such as clotting abnormalities or 
microvascular disease that place diabetic patients at higher risk of CHD (31).  In yet 
another study, although somewhat controversial, Haffner et al. demonstrated that 
diabetics without prior MI have similar mortality rates compared to non-diabetics with 
prior MI even after adjusting for LDL/HDL cholesterol levels, triglycerides, smoking, 
  
  7 
and hypertension (HR=1.2, 95% CI: 0.6-2.4) leading the authors to conclude that diabetic 
patients should be treated as aggressively as non-diabetic patients with prior MI (32). 
Whether the increased mortality risk seen in diabetics can be explained by 
inherent biological differences between diabetics and non-diabetics or whether treatment 
differences in terms of the quality of care diabetics receive post-MI account for the 
increased mortality has been extensively debated and is explored in our own study via 
analysis of the Cooperative Cardiovascular Project (CCP), a national database established 
to examine quality of care for Medicare patients hospitalized with AMI between 1994-
1995.  First, however, in order to fully understand the background of this debate and the 
results from our own study, a review of the biology of AMI in diabetics and the 
established treatment guidelines for the care of diabetic patients post-MI during 1994-
1995 (the time period when initial data for the CCP cohort was collected) is warranted. 
 
Understanding the Pathophysiology of Atherosclerosis and AMI in Diabetics 
Traditional risk factors for AMI such as hyperlipidemia, obesity, and hypertension 
affect diabetics and non-diabetics in a similar fashion.  In a follow-up study of the United 
Kingdom Prospective Diabetes Study (UKPDS), Turner et al. demonstrated that among 
type 2 diabetics increased low density lipoprotein cholesterol (LDL), decreased high 
density lipoprotein cholesterol (HDL), hyperglycemia, hypertension, and smoking were 
all risk factors for coronary artery disease including fatal and non-fatal myocardial 
infarction (33).  Interestingly, the study showed that lipids (increased LDL and decreased 
HDL) and hypertension were more predictive as risk factors for non-fatal or fatal 
myocardial infarction rather than hyperglycemia (33).  From the results of their study, the 
authors concluded that type 2 diabetics have similar risk factors for coronary artery 
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disease as non-diabetics.  However, even after controlling for these traditional risk 
factors, there are additional risk factors which may partially explain the increased risk of 
cardiovascular disease which diabetes confers on patients.  Insulin resistance leading to 
hyperglycemia, hyperinsulinemia, atherogenic dyslipidemia, and a prothrombotic state 
are independent risk factors especially in type 2 diabetes that increase the risk of 
cardiovascular mortality (12, 34).  For example, atherogenic dyslipidemia, characterized 
by three lipoprotein abnormalities—elevated very-low density lipoprotein (VLDL), small 
dense LDL particles, and low HDL cholesterol, appears frequently in those with insulin 
resistance.  Besides elevated LDL cholesterol, these lipid abnormalities may 
independently lead to atherosclerosis (12).  Additionally, Zareba et al. demonstrated in a 
study examining 1,045 non-diabetic and diabetic patients post-MI that diabetic patients, 
especially insulin-dependent diabetics, had higher levels of von Willebrand factor as 
compared to non-diabetics after adjusting for confounders (35).  The authors concluded 
that endothelial damage is most likely one of the primary mechanisms leading to the 
increased mortality seen in diabetics post-MI.  In fact, it has been shown that diabetics 
have impaired endothelium-dependent relaxation (18, 36).   
In terms of hyperglycemia, results from another UKPDS follow-up study in 2000, 
revealed that for every 1% decrease in HbA1c levels, the risk for myocardial infarction in 
diabetics could be reduced by 14% (37).  Stevens et al. also used data from the UKPDS 
to examine differences in risk factors for cardiovascular mortality due to myocardial 
infarction and stroke (38).  They found that those with fatal MIs had higher HbA1c 
levels, measured within 2 years of diabetes diagnosis, as compared to those with nonfatal 
MIs suggesting that long-term hyperglycemia impacts mortality rates within a diabetic 
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cohort.  Hyperglycemia, via the presence of advanced glycosylation end products, is 
theorized to be one of the primary causes underlying this endothelial dysfunction and 
may lead to an acceleration in atherogenesis (18, 39).   
Additionally, in the setting of an acute MI, there are additional abnormalities that 
place diabetics at increased risk for mortality.  Central to the pathophysiology of AMI is 
platelet aggregation and thrombosis (Figure 6).  It is estimated that 90% of AMIs are 
caused by an acute thrombus overlying an atherosclerotic coronary artery plaque (40).  
The thrombus leads to further narrowing and complete occlusion of the coronary artery 
leading to ischemia of the heart muscle (40).  When a plaque ruptures, platelets are 
activated via exposure to the underlying subendothelial collagen triggering the 
coagulation pathway and thrombus formation (40).  Activated platelets also release potent 
vasoconstrictors such as thromboxane, which contributes to further narrowing of the 
vessels (40).  Because of the metabolic derangements found in diabetes, research has 
focused on characterizing the pathophysiology of platelet function in diabetics presenting 
with AMI.  In general, diabetics have increased platelet aggregability and an increased 
procoagulant state as measured by fibrinogen levels and plasminogen activator inhibitor-
1 (12, 41, 42).  Studies have shown that platelets from diabetic patients produce increased 
prostaglandins and thromboxane A2 (TXA2) relative to platelets from non-diabetic 
patients (18, 43).  The increased prostaglandins and TXA2 expose fibrinogen binding 
sites on platelets, leading to the observed increase in platelet aggregation in diabetic 
patients (44).  Activated platelets also appear to be increased in diabetic patients even in 
the absence of detectable vascular lesions (18).  Because diabetics are prone to a more 
hypercoagulable state, this suggests that they may more easily form thrombi causing 
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them to experience more severe AMIs and thus have worse outcomes as compared to 
their non-diabetic counterparts. 
            
 
 







 Myocardial Ischemia 
 
   
 
Figure 6: Pathophysiology of Acute Myocardial Infarction-the Role of Platelets and 
Thrombus Formation Leading to Myocardial Ischemia.  IL-1:interleukin-1; TNF: 
tumor necrosis factor-alpha.  Source: www.images.med.  Original figure taken 
from: Murad M, Henry T: Unstable Angina. Current Treatment Options in 
Cardiovascular Medicine. 2(1):37-54.  
Exploring Differences in Quality of Care: Diabetics and the Elderly 
Besides understanding how biological factors may confer an increased risk of 
morbidity and mortality in diabetic patients with CHD, other research has centered on 
identifying whether differences exist between diabetics and non-diabetics in terms of the 
quality of care they receive.  It has been noted that the clinical presentation of diabetics 
with AMI may differ from that of a non-diabetic, with diabetics having “atypical 
symptoms” due to autonomic neuropathy leading ultimately to a decreased recognition of 
AMI (12).  Because of impaired angina recognition by both patient and caregiver, 
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important intervention therapies may be delayed and morbidity and mortality rates are 
increased (16).   
However, more concerning have been the studies that demonstrate when diabetics 
suffer AMIs, they are unlikely to receive the same therapeutic interventions as their non-
diabetic counterparts (21, 23, 24, 45-48).  In a retrospective study of 1,982 Australian 
patients, Lim et al. examined treatment differences between diabetics and non-diabetics 
presenting with AMI between 1988-1994.  Diabetics were less likely to be prescribed the 
following therapies on admission: aspirin (76% vs. 85%, p<0.005), beta-blockers (41% 
vs. 53%, p<0.001), or streptokinase (25% vs. 43%, p<0.001) (23).  Similarly, Vaccarino 
et al. also demonstrated in a larger study examining 160,773 patients aged 30 to 69 
hospitalized with AMI between 1994-1998 that diabetics were less likely to receive 
thrombolytic therapy (18.8/22.7% diabetic women/men vs. 27.6/32.5% non-diabetic 
women/men), aspirin (74.7/80.5% diabetic women/men vs. 81.2/86.6% non-diabetic 
women/men , oral beta-blockers (33.0/37.8% diabetic women/men vs. 37.9/42.3% non-
diabetic women/men), or alternative reperfusion (9.7/11.7% diabetic women/men vs. 
14.0/17.6% non-diabetic women/men) (47).  Norhammar et al. in a retrospective analysis 
of a Swedish registry also investigated treatment differences between diabetics and non-
diabetics hospitalized with AMI between 1995-1998.  During hospitalization, diabetics 
were less likely to be treated with heparins (37% vs. 43%, p<0.001), intravenous beta-
blockers (29% vs. 33%, p<0.001), thrombolysis (31% vs. 41%, p<0.001) and acute 
revascularization (4% vs. 5%, p<0.003).  Even after adjustment for comorbidities, 
diabetics were still significantly less likely to be treated with reperfusion therapy 
(OR=0.83, 95% CI: 0.77-0.89), heparins (OR=0.88, 95% CI: 0.82-0.94), statins 
  
  12 
(OR=0.88, 95% CI: 0.80-0.97), or undergo revascularization within 14 days of hospital 
discharge (OR=0.86, 95% CI: 0.75-0.98) (21).   
Using the same database as we did in our present study, Berger et al. analyzed 
data from the CCP cohort (between January 1994-February 1996) and established that 
diabetics were statistically less likely to receive aspirin on arrival, beta-blockers on 
discharge, receive thrombolytics, undergo cardiac catherization, or coronary angioplasty.  
Across subgroups of diabetics, patients on insulin therapy consistently received the least 
appropriate care (24).  A major limitation, however, of all the above studies is that 
contraindications to medical therapy were not accounted for in these analyses.  Given the 
fact that diabetics are known to have more comorbidities, the finding of decreased use of 
evidence-based therapies may in fact be due to more contraindications to therapy 
secondary to the increased comorbidities diabetics face.   
Both Chowdhury et al. and Krumholz et al. addressed this issue in their respective 
studies.  Like the other authors discussed above, Chowdhury et al. also examined rates of 
prescription use among a small British cohort of 374 patients between January 1995-
December 1995 hospitalized with their first MI.  Patients were prospectively evaluated 
during admission and at one year.  At follow-up, diabetic patients were statistically more 
likely to have evidence of left ventricular failure (47.7% vs. 28.0%, p<0.01).  However, 
the proportion of diabetic patients with left ventricular failure that were prescribed 
angiotensin-converting enzyme inhibitors (ACE-Is) was less (61% vs. 73.6%, p<0.01).  
The same pattern was observed for lipid lowering therapy.  Although total cholesterol 
values (>5.5 mmol/L) were significantly higher among diabetic patients at time of 1 year 
follow-up, they were less likely to be on lipid lowering therapy (27.9% vs. 37.5%, 
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p<0.05).  Although it did not reach statistical significance, the authors also found that the 
proportion of diabetic patients on beta-blockers and aspirin was lower than for non-
diabetics.  When closely examined, diabetics had less contraindications to therapy as 
compared to non-diabetics.  The authors concluded that the lower usage of these therapies 
was not based on contraindications but rather appeared to have little scientific-based 
justification or explanation (48).   Krumholz et al. also adjusted for contraindications to 
therapy by limiting their cohort to ideal candidates for therapy.  From analysis of CCP 
data from 4 states, Alabama, Connecticut, Iowa, and Wisconsin, non-diabetics were more 
likely to receive aspirin during hospitalization, aspirin and beta-blocker therapy at 
discharge, and to undergo cardiac procedures.  Using results from a multiple logistic 
regression model, the authors reported that a history of diabetes was associated with 
decreased use of aspirin (OR=0.81, 95% CI: 0.70-0.94) and that use of aspirin at 
discharge was associated with decreased mortality rates 6 months post discharge 
(OR=0.77, 95% CI: 0.61-0.98) (46).  
 Like diabetics, evidence exists that elderly patients are also less likely to receive 
appropriate evidence-based care.  Udvarhelyi et al. retrospectively examined differences 
in processes and outcomes of care post-MI among a Medicare population (n=218,247 
patients).  The authors found that use of procedures such as angiography, coronary artery 
bypass graft (CABG), and percutaneous transluminal coronary angioplasty (PTCA) 
decreased with every 5 year increase in age, after adjustment for comorbidities, 
suggesting that the most elderly patients are the least likely to undergo procedures as 
compared to younger patients within the same Medicare population.  Other authors have 
also reported similar findings that suggest elderly patients are less likely to receive 
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evidence-based care (10, 46, 49-55).  Using data from the Worcester Heart Attack Study, 
a prospective longitudinal study of 9,336 Worcester, Massachusetts residents hospitalized 
with confirmed AMI between 1975-1997, Jackson et al. examined trends in aspirin 
utilization and long-term outcomes.  The authors demonstrated that over three time 
periods (1975-1978, 1986-1988, and 1995-1997) diabetics and the elderly were less 
likely to receive aspirin therapy.  They also showed that over a 10-year follow-up period, 
patients treated with aspirin during initial hospitalization for AMI had increased survival 
after controlling for study year, patient age, sex, comorbidities, AMI characteristics, and 
development of heart failure or cardiogenic shock during initial hospitalization 
(HR=0.85, 95% CI: 0.78-0.92) (56). Given the results from studies like this one, it may 
be appropriate to conclude that elderly diabetic patients may be the group least likely to 
receive appropriate care due to the “double bias” against the elderly and diabetics in 
general. 
In an attempt to understand why certain populations such as the elderly and 
diabetics do not receive appropriate evidence-based care, physician adherence to practice 
guidelines has been extensively studied and various attempts to improve quality of care 
have been initiated.  One such attempt was the development of the CCP cohort.  In 1992, 
as part of the Health Care Quality Improvement Initiative, the Health Care Financing 
Administration (HCFA, renamed in 2001 as the Centers for Medicare & Medicaid 
Services [CMS]) created the CCP.  The CCP was designed with the following four 
objectives:  
1) to develop quality indicators describing use of interventions in an ideal group 
of patients with AMI,  
2)  to measure the quality of care by relying on these indicators for AMI patients 
in Alabama, Connecticut, Iowa, and Wisconsin,  
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3) to use these measurements to direct hospitals to develop quality improvement 
mechanisms and,  
4) to help the HCFA use the CCP as a prototype in the development of similar 
quality improvement efforts for other conditions besides AMI (53).   
 
Because of its success, the CCP was subsequently nationally expanded and is an ongoing 
initiative.  The CCP is a large well-known cohort that has been validated.  Numerous 
studies have been published over the past decade using data from the CCP that not only 
have described treatment practices for patients with AMI but also have described changes 
over time with regards to the quality of care patients hospitalized with AMI have received 
(10, 22, 24, 51, 52, 55, 57, 58).  Likewise, our study will also use data from the CCP to 
examine quality of care.  However, this will be the first time that data on long-term 
mortality for diabetics will be presented controlling for differences in quality of care.  
Because our study examines 10-year mortality, it is important to recognize and 
understand the scientific environment at the time of our study and the potential paradigm 
shifts in medical practice during this time period especially when interpreting results and 
formulating conclusions.  Thus, a brief history of some of the major controversies during 
this time period is presented below. 
 
Practice Guidelines: Management of AMI and Diabetes 
 As mentioned above, the CCP was developed in 1992 with four objectives.  The 
first objective was to develop quality indicators describing use of interventions in an ideal 
group of patients with AMI.  In order to achieve this objective, 11 quality of care 
indicators were developed, based primarily on the 1990 American College of Cardiology 
(ACC)/American Heart Association (AHA) treatment guidelines for the secondary 
prevention of AMI.  Some of the established guidelines that became the basis for these 
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quality of care indicators were as follows: use of beta-blockers at admission/discharge, 
use of aspirin at admission/discharge, use of ACE-Is in patients with low left ventricular 
ejection fraction (LVEF <40%), avoidance of calcium channel blockers in patients with 
low left ventricular ejection fraction (LVEF <40%), smoking cessation counseling, use of 
percutaneous transluminal coronary angioplasty (PTCA) within six hours of onset of 
chest pain who meet criteria for thrombolysis, use of thrombolytics on admission, 
administration of heparin, and use of intravenous nitroglycerin for persistent chest pain 
(53, 59).    
Although it was recognized at this time that diabetics had increased mortality 
post-MI, no separate guidelines for the secondary prevention of AMI existed for diabetic 
patients during this time period.  Thus, specific guidelines for diabetics were only 
developed after 1995, after our study was initiated (12).  Although the 1990 guidelines 
did not specifically address diabetics, there were prevailing debates within the scientific 
community about the applicability and the appropriateness of these therapies for diabetic 
patients that merit discussion and may provide a framework for understanding why 
diabetics may have been less likely to receive certain medications.   
The 1990 ACC/AHA guidelines advised caution with regards to beta-blocker use 
as secondary prevention in diabetics post-MI.  The guidelines stated that one of the 
relative contraindications to beta-blockade was “difficult to control insulin-dependent 
diabetes” but did not further specify how this was defined (59).  The argument against 
beta-blocker use in diabetics was the theoretical belief that beta-blockers masked the 
symptoms of hypoglycemia especially by blunting reflex tachycardia.  However, studies 
showed that there was no significant increase in the incidence of clinically important 
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hypoglycemic events (60).  Likewise, controversy also existed with regards to aspirin 
therapy.  In particular, aspirin was thought to increase the risk of ocular hemorrhages 
among patients with diabetic retinopathy.  Although the results from the Early Treatment 
Diabetic Retinopathy Study (ETDRS) published in 1992 demonstrated that aspirin did 
not increase the risk of ocular hemorrhage and that there was a small reduction in 
cardiovascular events in diabetics (61), the American Diabetes Association (ADA) did 
not officially recommend aspirin for all diabetics until 1997 (62). 
Additionally, one of the major controversies at this time was regarding glucose 
control and macrovascular complications.  In 1993, one year prior to the start of our 
study, the Diabetes Control and Complications Trial (DCCT) showed that intensive 
control in type 1 diabetics helped decrease microvascular complications and showed a 
non-statistically significant trend towards a reduction in macrovascular complications 
(63, 64).  Whether similar intensive glycemic control impacted outcomes for type 2 
diabetics was unknown at the start of our study, however there were several ongoing 
studies addressing this issue at that time.  Two of the most important studies were the 
Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 
Study and the United Kingdom Prospective Diabetes Study (UKPDS)—both of which 
later impacted practice guidelines. 
The findings from the DIGAMI study, a randomized controlled trial, were 
published in 1995 and demonstrated that diabetic patients randomized to an intensive 
insulin regimen post-MI had decreased in-hospital and 1-year mortality (65).  Findings 
from the 3-year follow-up study published in 1997 also demonstrated that among those 
that had been randomized to the intensive insulin regimen, an 11% reduction in mortality 
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3 years post treatment was achieved (63, 66).  In 1998, results from a randomized 
controlled trial (RCT) embedded within the UKPDS1 were published.  This portion of the 
UKPDS was designed to determine whether intensive therapy would reduce diabetic 
microvascular and macrovascular complications.  Although it did show an improvement 
in microvascular outcomes, it only showed a borderline decrease in macrovascular 
disease (67, 68).  Reception of these findings by the scientific and medical community 
were initially mixed but both studies became landmark articles that impacted practice 
guidelines especially with regards to the use of insulin and oral hypoglycemics to achieve 
better glycemic control.  Because our study spans the time period when major changes in 
quality of care and practice guidelines occurred, we will examine long-term mortality 
outcomes at two time periods: pre- and post-1997/1998.  We chose the years 1997/1998 
because as discussed above, these were the years that aspirin therapy for diabetics was 
endorsed by the ADA and the results of the DIGAMI and UKPDS studies were 
published.   
II. Statement of Purpose, Specific Aims, and Hypotheses 
The purpose of this study was to examine overall outcomes for older diabetic 
patients presenting with AMI and to examine the factors associated for the increased 
mortality risk conferred on diabetics hospitalized with AMI by utilizing a national 
database, the Cooperative Cardiovascular Project (CCP).   Our aims were: 
1) To measure and compare 10-year mortality rates for diabetic and non-diabetic 
patients hospitalized with AMI. 
 
2) To measure compliance rates with established guidelines in place during 1994-
1995 regarding cardiac medications as a secondary prevention strategy among 
diabetic and non-diabetic patients hospitalized with AMI.  
                                                 
1 The UKPDS was a 20 year prospective trial that recruited 5,102 patients with type 2 diabetes from 23 
clinical centers in England, Scotland, and Northern Ireland. 
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3) To investigate the role of statin and diabetic therapies (insulin/oral 
hypoglycemics) in decreasing 3 and 10-year mortality rates for diabetics 
hospitalized with AMI. 
 
We hypothesize that: 
1) 10-year mortality rates for diabetics will be higher as compared to non-diabetic 
patients before and after adjustment for quality of care indicators. 
 
2) Diabetic patients will be less likely to receive appropriate cardiac medications for 
secondary prevention.  
 
3) Both statin and diabetic therapies (insulin/oral hypoglycemics) will be associated 




We utilized the Cooperative Cardiovascular Project (CCP), a national database of 
Medicare patients, (n=234,769) aged 65 or older admitted to non-governmental acute 
care hospitals in the United States and Puerto Rico.   As mentioned previously, the CCP 
was designed with four objectives: 1) to develop quality indicators describing use of 
interventions in an ideal group of patients with AMI; 2) to measure the quality of care by 
relying on these indicators for AMI patients in Alabama, Connecticut, Iowa, and 
Wisconsin; 3) to use these measurements to direct hospitals to develop quality 
improvement mechanisms; and 4) to help the HCFA use the CCP as a prototype in the 
development of similar quality improvement efforts for other conditions besides AMI 
(53).  
 
Sample Population & Data Collection 
All bills submitted by acute care hospitals (UB-92 claims form data) and 
contained in the Medicare National Claims History File, composed of Part A Medicare 
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claims, were used to identify discharges (55).  The Medicare National Claims History 
File includes patients treated under fee-for-service plans but does not include bills for 
those treated under Medicare managed care risk contracts (55).  The sample was limited 
to patients, aged 65 or older, discharged alive with a principal diagnosis of AMI utilizing 
the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9), 
code 410.xx.   Codes where the fifth digit was a “2” (410.x2) were excluded since this 
represented an admission for a subsequent episode of care (10).  With the exception of 
five states (Alabama, Connecticut, Iowa, Wisconsin, and Minnesota), patients were 
identified during an eight-month period using the Medicare National Claims History File.  
All discharge dates were between February 1994 and July 1995.   Because Alabama, 
Connecticut, Iowa, and Wisconsin were the original four pilot states, hospitalizations 
were sampled initially between June 1 and December 31, 1992 and then re-measured 
between August 1 and November 30, 1995 (55).  An ongoing study, the Minnesota 
Clinical Comparison and Assessment Project (MCCAP) caused sampling in that state to 
be delayed until April-November 1995 (51, 55).   
 
Data Collection: 
Medical record abstraction was performed by trained abstractors at two clinical 
data abstraction centers established by the HCFA (now CMS).  Predefined variables were 
identified from the hospital record and entered directly into a computer database by 
trained technicians (51).  Random re-abstraction of 1,078 pairs of CCP cases was utilized 
to ensure data reliability.  Cases were re-abstracted between March 1, 1995 and 
November 30, 1995 (7).  Variable agreement, as shown in Table 2 below, varied from 
91.6% to 98.3% (Kappa, 0.46-0.95) (7, 10, 51).  Quality indicator reliability defined as 
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the agreement rate between two abstractors assessing patient eligibility for a quality 
indicator and subsequent receipt of the indicator varied from 93.5% to 98.6% (Kappa, 
















Opportunities to Improve Care (“Ideal” Candidates who did not receive 
appropriate therapy) 
Therapy Usage     
  Aspirin during hospitalization 6.9 96.1 0.69 
  Aspirin at discharge 5.8 96.2 0.41 
  Beta-blockers at discharge 3.5 97.5 0.64 
  ACE inhibitor at discharge 3.1 98.6 0.76 
  Thrombolysis administered 3.4 95.8 0.41 
  Reperfusion given 2.9 93.8 0.53 
  Smoking cessation counseling   

















AMI Confirmation 88.5 94.6 0.72 
Therapy Usage     
  Aspirin during hospitalization 77.3 95.6 0.88 
  Aspirin at discharge 52.8 94.8 0.90 
  Beta-blockers at discharge 32.0 97.4 0.94 
  ACE inhibitor at discharge 27.2 98.1 0.95 
  Thrombolysis administered 14.0 98.3 0.93 
  Reperfusion given 20.8 97.4 0.92 
  No calcium blockers at 
discharge 70.3 97.6 0.94 
  Smoking cessation counseling 
at discharge 9.5 91.6 0.46 
Table 3: Reliability findings for CCP composite quality indicators representing 
opportunities to improve care (Modified-Huff et al., Table 5 (7)) 
Table 2: Reliability findings between AMI confirmation and CCP indicators 
(Modified-Huff et al., Table 3 (7)) 
AMI and Diabetes Definitions: 
The criteria for a confirmed AMI was the following: a discharge diagnosis of an 
AMI and chart documentation of either a creatine-kinase-muscle-brain isoenzyme (CK-
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MB) fraction greater than 0.05 or a lactate dehydrogenase (LDH) level more than 1.5 
times normal with a LDH-1 level higher than a LDH-2 level or two of the following three 
criteria: chest pain, a two-fold elevation of the CK level, or evidence of a new AMI on an 
electrocardiogram.  We did not use troponin levels since they were not widely in use 
during 1994-1995, hence the necessary data was lacking.  The diagnosis of diabetes 
mellitus was based on chart documentation rather than diagnosis code.  We did not use 
admission serum glucose levels or HbA1c levels as a criterion for the diagnosis of 
diabetes.  We also did not distinguish type 1 diabetes from type 2 diabetes in our 
subsequent analyses.   
 
Quality of Care Indicators 
 Table 4 lists the quality of care indicator definitions, eligibility, and exclusion 
criteria used in this study.  Quality of care indicators were developed by a steering 
committee convened by HCFA and the American Medical Association during the pilot 
phase of the CCP (53).  The quality of care indicators were based primarily on the 
ACC/AHA treatment guidelines for AMI (53).  Each indicator had specific criteria to 
determine potential “eligible” candidates (those who could have received an 
intervention).  This population was subsequently subdivided into two groups: a) ideal 
candidates—patients for whom treatment should be indicated; and b) less-than-ideal 
candidates—patients for whom treatment was contraindicated, controversial, or for whom 
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Table 4: Quality of Care Indicators-Eligibility and Exclusion Criteria 
Aspirin Prescribed During Hospitalization 
  Eligible: All patients with confirmed acute myocardial infarction (AMI) 
  Exclusions: Bleeding on admission, history of peptic ulcer disease or internal bleeding, 
coagulopathy, chronic liver disease, allergy to aspirin, admission platelet count 
<100x109/L, hemoglobin <10g/dL, hematocrit <30%, serum creatinine 
>3mg/dL, treatment with warfarin on admission, metastatic cancer, or terminal 
illness 
 Criterion: Received aspirin on day 1 or 2 
Aspirin Prescribed at Discharge 
  Eligible: All patients with confirmed acute myocardial infarction (AMI) discharged 
alive and eligible for discharge therapies 
  Exclusions: Bleeding on admission or during hospitalization, history of peptic ulcer disease 
or internal bleeding, acute upper gastrointestinal tract disorder during 
hospitalization, bleeding, coagulopathy, chronic liver disease, allergy to 
aspirin, admission platelet count <100x109/L, hemoglobin <10g/dL, 
hematocrit <30%, serum creatinine >3mg/dL, treatment with warfarin on 
discharge, metastatic cancer, or terminal illness 
  Criterion: Aspirin prescription at discharge 
Beta-Blocker Prescribed During Hospitalization 
  Eligible: All patients with confirmed acute myocardial infarction (AMI) 
  Exclusions: Heart rate <60/min, systolic blood pressure <100mm/Hg, second or third-
degree heart block, heart failure, left ventricular ejection fraction <50%, 
bifasicular block, allergy or intolerance to beta-blockers, history of asthma, 
chronic obstructive pulmonary disease, peripheral vascular disease, shock 
  Criterion: Received beta-blockers on day 1 or 2  
Beta-Blocker Prescribed at Discharge 
  Eligible: All patients with confirmed acute myocardial infarction (AMI) discharged 
alive and eligible for discharge therapies 
  Exclusions: Heart rate <50/min at discharge (not currently on beta-blocker), systolic blood 
pressure <100mm/Hg at discharge (not currently on beta-blocker), second or 
third-degree heart block, heart failure and left ventricular ejection fraction 
<50%, left ventricular ejection fraction <30% or described as severe 
dysfunction, bifasicular block, allergy or intolerance to beta-blockers, history 
of asthma, chronic obstructive pulmonary disease, peripheral vascular disease, 
shock or hypotension during hospitalization 
  Criterion: Beta-blocker prescription at discharge 
Angiotensin-converting enzyme inhibitor (ACE-I) Prescribed at Discharge 
  Eligible: All patients with confirmed acute myocardial infarction (AMI) with left 
ventricular ejection fraction <40% or described as severe or moderate 
dysfunction discharged alive and eligible for discharge therapies 
  Exclusions: Aortic stenosis, allergy or intolerance to ACE-Is, systolic blood pressure 
<100mmHg at discharge (not currently on ACE-I), serum creatinine >2mg/dL 
  Criterion: ACE-I prescription at discharge 
Receipt of Primary Percutaneous Transluminal Coronary Angioplasty (PTCA) 
  Eligible: All patients with confirmed acute myocardial infarction (AMI), with ST 
elevation or left bundle branch block on admission electrocardiogram, and 
onset of symptoms within 12 hours 
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  Exclusions: Stroke, coagulopathy, bleeding on admission, chronic liver disease, history of 
internal bleeding or peptic ulcer disease, recent surgery (defined as within the 
past 2 months), recent cardiopulmonary resuscitation, recent trauma, age >80 
years, use of warfarin prior to arrival, evidence that thrombolysis was rejected 
by patient or physician after initial consideration, cardiac catherization without 
angioplasty within 12 hours after admission 
  Criterion: Receipt of PTCA within 24 hours of admission 
Timing of Thrombolytic Therapy 
  Eligible: Same as receipt of PTCA 
  Exclusions: Same as receipt of PTCA 
  Criterion: Time from admission to initiation of thrombolytic therapy 
 
Smoking Cessation Counseling 
  Eligible: All patients with confirmed acute myocardial infarction (AMI) discharged 
alive with cigarette use within year of admission 
  Exclusions: None 
  Criterion: Chart documentation of counseling on smoking cessation 
 
Exclusion/Inclusion Criteria 
Modified from Burwen et al., “National and State Trends in Quality of Care for Acute 
Myocardial Infarction Between 1994-1995 and 1998-1999: The Medicare Health Care Quality 
Improveme t Program” (Table 1) (10) 
Our study sample included 234,769 Medicare patients aged 65 years or older 
hospitalized with confirmed AMI and who were discharged alive.  Only the first AMI 
admission was included regardless of whether a patient was hospitalized for AMI more 
than once during the sample period (51).  We excluded all transferred patients due to the 
inability to determine discharge medications.  Those who were terminally ill (those with 
less than 6-month survival as documented in the hospital records), those with “do not 
resuscitate” (DNR) instructions, or those who had end-stage renal disease were also 
excluded.   After excluding those who were less than 65 years old, had terminal illness, or 
who were transferred from another hospital, our final study sample was 203,658 patients.  
For our quality of care analyses, we further restricted the cohort to ideal candidates only, 
using the specific criteria developed for these indicators as detailed in Table 4. 
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Demographic & Clinical Variables  
Our demographic variables were age, sex, and race.  Age was categorized as 65 to 
74 years, 75 to 84 years, and 85 years and older.  Race was dichotomized as white and 
nonwhite.  Clinical variables for each patient were collected from the medical record and 
included past medical history, medications on admission/discharge, and in-hospital 
characteristics and procedures.  Comorbidities were obtained from chart documentation 
and included the following: history of hypertension, stroke, congestive heart failure 
(CHF), renal dysfunction (serum creatinine >2.5mg/dL or blood urea nitrogen >40 
mg/dL), cancer, chronic obstructive pulmonary disease, history of myocardial infarction, 
previous percutaneous transluminal coronary angioplasty (PTCA), previous coronary 
artery bypass graft surgery (CABG), dementia, inability to ambulate, albumin level less 
than 3g/dL, left ventricular ejection fraction (LVEF) less than 0.35, and anemia 
(hematocrit <30).  Smoking status was also obtained as documented in the chart.  
Admission lab characteristics included respiratory rate greater than 25/min, prothrombin 
time greater than 16 seconds, pulse greater than 100/min, and evidence of a left bundle 
branch block on the admission electrocardiogram.  In-hospital clinical characteristics and 
procedures performed included recurrent chest pain, heart failure, stroke, creatine kinase 
levels more than four times the normal level, PTCA, CABG, and measurement of LVEF.  
Hospital length of stay was also abstracted.  Documentation of medications during 
admission included aspirin, beta blockers, and thrombolytic therapy.  Discharge 
medications included aspirin, beta blockers, ACE-Is, statins, and bronchodilators.  
Diabetic medications were identified and abstracted from a file listing all medications 
used by the cohort and included the following classes of medication: insulin, biguanides, 
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sulfonylureas, and glucosidase inhibitors.  Discharge disposition was coded as home, 
long-term care, or died.  Physician’s specialty was also abstracted based on information 
listed in the Medicare Part A claims (51).  Each physician’s identification number was 
linked with the HCFA directory of physician-reported specialties (51). 
 
Outcome Variable 
Our outcome variable was all-cause mortality 3 and 10 years after hospital 
discharge.  Mortality was determined by linking patient data with the Medicare 
Enrollment Database.  The Enrollment Database contains information on all beneficiaries 
ever enrolled in the Medicare program, including information on dates of death (69).  
These dates are a compilation of data derived from discharge dates of billing records, 
which indicate any discharge dispositions of death, and from the Master Beneficiary 
Record, included as part of Social Security records (52).   
 
Statistical Analysis: 
Statistical analysis using 2-sided t-tests for differences in means, chi-squared tests 
for comparison of categorical variables, and Cox proportional regression was used.  The 
data was primarily analyzed according to diabetic status.  After testing and confirming 
graphically that the proportionality assumption for Cox regression was met, a Cox 
proportional hazards model was used to assess mortality differences.  For all mortality 
analyses time “0” was defined as patient admission to the hospital.  We adjusted for 
potential confounders by including the variables collected as described above:  
demographics, clinical variables, physician specialty, hospital characteristics, and quality 
of care indicators.  A quality of care composite model was constructed that represented 
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an opportunity-level composite score (7).  Eight quality of care indicators were used to 
calculate the opportunity and composite score for each patient: aspirin, acute reperfusion, 
thrombolytics and beta-blocker on admission; aspirin, beta-blocker, ACE-I, and smoking 
counseling at discharge.2  A series of Cox proportional hazards models with adjustment 
for clustering3 on hospitals were constructed that sequentially adjusted for diabetic status, 
demographics, clinical and medical history, and finally quality of care.  We calculated 
both unadjusted and adjusted hazard ratios with their respective 95% confidence intervals 
(CIs).  Kaplan-Meier survival curves were plotted and log-rank tests were calculated to 
determine statistical differences between curves.  We also created a diabetic risk-adjusted 
model to determine the association between prescribed use of insulin, sulfonylureas, 
biguanides, and statin therapy with 3 and 10-year survival.  Similarly, we calculated both 
unadjusted and adjusted hazard ratios with their respective 95% confidence intervals 
(CIs).  Statistical significance for p-values was set at α=0.05.  All analyses were 
performed using STATA 8.00 (STATA Corp, College Station, Tex). 
 
IV. Statement of Student Contribution 
 This work was a collaboration between many individuals.  Both Dr. JoAnne 
Foody and Dr. Barbara Gulanski provided valuable feedback throughout the thesis 
process.  Dr. JoAnne Foody and Dr. Harlan Krumholz provided access to the CCP 
database.  All statistical analyses were performed by Yun Wang, Ph.D. (Center for 
Outcomes Research and Evaluation, Yale University).  I, along with Drs. Foody and 
                                                 
2 For example, if a patient was eligible for both aspirin on admission and beta-blocker and ACE-I at 
discharge, then this patient had three opportunities (denominator).  However, if this patient only received 
two of these therapies (numerator) the overall composite score for this patient would be 0.66. 
3 The statistical command “cluster” specifies observations as independent across groups (clusters) but not 
necessarily within groups  [70]. Stata Corporation. Statistics Data Management Graphics Reference G-0. 
College Station: Stata Corporation; 1997.      
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Gulanski, developed the aims, hypotheses, and collectively analyzed the conclusions of 
this study.  All literature searches were performed by this author.   
 
V. Results 
Characteristics of the Sample 
 Diabetics comprised 32% (64,648) of the sample.  The demographic and clinical 
characteristics of diabetic and non-diabetic patients are shown in Table 5 below.   
 
Table 5: Baseline Patient Characteristics By Diabetic Status 
No. of Patients with 
Characteristic by Diabetic 




(N=139,010) Characteristics p 
Demographic information    
    Age, mean (SD) 75.3 (6.8) 76.5 (7.5)      <0.001 
    Age 65 – 74 36,283 (49.9) 62,110 (44.7) <0.001 
    Age 75 – 84 25,606 (39.6) 54,069 (38.9) 0.603 
    Female 37,226 (52.9) 64,827 (46.6) <0.001 
    White 55,764 (86.3) 127,958 (92.1) <0.001 
     
Medical History and Comorbid Conditions    
    Previous MI 22,601 (35.0) 39,278 (28.3) <0.001 
    Previous PTCA 5,262 (8.1) 9,563 (6.9) <0.001 
    Previous CABG 9,195 (14.2) 16,175 (11.6) <0.001 
    History of CHF 18,705 (28.9) 23,883 (17.2) <0.001 
    History of CVA 10,893 (16.9) 16,244 (11.7) <0.001 
    History of Chest Pain 18,711 (28.9) 38,573 (27.8) <0.001 
    Hypertension 46,031 (64.8) 80,149 (57.7) <0.001 
    Peripheral Vascular Disease  9,427 (13.3) 11,249 (8.5) <0.001 
    Current Smoker 7,000 (10.8) 22,691 (16.3) <0.001 
    Dementia 3,412 (5.3) 8,098 (5.8) <0.001 
    Unable to Ambulate 16,266 (25.2) 26,443 (19.0) <0.001 
    
Admission Characteristics    
    Creatinine > 2.5 mg/dL or BUN > 40 mg/dL 8,882 (13.7) 10,472 (7.5) <0.001 
    Creatinine, mean (SD) 1.5 (1.1) 1.3 (0.9) <0.001 
    BUN, mean (SD) 25.5 (14.3) 21.8 (11.7) <0.001 
    Albumin < 3 g/dL 3,551 (5.5) 5,957 (4.3) <0.001 
    Hematocrit < 30  3,729 (5.8) 6,244 (4.5) <0.001 
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Table 5: Baseline Patient Characteristics By Diabetic Status 
No. of Patients with 
Characteristic by Diabetic 




(N=139,010) Characteristics p 
    Prothrombin Time > 16 sec 3,871 (6.0) 7,350 (5.3) <0.001 
    Respiratory Rate > 25/min 13,795 (21.3) 22,126 (15.9) <0.001 
    Pulse > 100/min 3,794 (5.9) 7,315 (5.3) <0.001 
    CVA on Admission 720 (1.1) 1,459 (1.1) 0.346 
    Left Bundle Branch Block 4,635 (7.2) 7,559 (5.4) <0.001 
    LVEF < 0.35 11,819 (18.3) 19,855 (14.3) <0.001 
     
Medications During Admission    
    Aspirin 28,884 (83.0) 66,235 (85.6) <0.001 
    Beta Blockers 25,147 (50.4) 58,781 (56.3) <0.001 
    Thrombolytics 2,270 (49.8) 7,280 (63.2) <0.001 
    
Hospital Procedures and Course    
    Cardiac Catheterization 23,951 (33.7) 52,173 (37.5) <0.001 
    PTCA 7,689 (11.9) 21,860 (15.7) <0.001 
    CABG 5,920 (9.2) 12,595 (9.1) 0.479 
    LVEF measured 41,602 (64.4) 89,860 (64.6) 0.201 
    Creatine Kinase > 4 times normal level 18,376 (28.4) 44,911 (32.3) <0.001 
     <0.001     Mean (SD) Length of Stay, if LOS ≤30 days 7.38 (5.0) 6.82 (4.7) 
     
Discharge disposition    
     Home 39,466 (61.1) 87,298 (62.8) 0.480 
     Discharged to long term care 5,399 (8.4) 10,803 (7.8) <0.001 
     Died 7,912 (12.2) 14,108 (10.2) <0.001 
    
* Table values are mean ± SD for continuous variables and No. (%) for categorical variables.  
Percentages may not sum to 100% due to rounding. 
MI=Myocardial Infarction; PTCA=Percutaneous Transluminal Coronary Angioplasty 
CABG=Coronary Artery Bypass Graft; CHF=Congestive Heart Failure 
CVA=Cerebral Vascular Accident; BUN=Blood Urea Nitrogen; Hct=Hematocrit 
LVEF=Left Ventricular Ejection Fraction 
 
Compared to non-diabetics, diabetics were younger (75 vs. 76, p<0.001).  A 
greater proportion of diabetics were female (53%, p<0.001) and nonwhite (86.3% vs. 
92.1%, p<0.001).  With regards to medical history and comorbidities, diabetics were 
more likely to have had a previous MI (35% vs. 28.3%), a history of CHF (28.9% vs. 
17.2%) or stroke (16.9% vs. 11.7%), or had previous revascularization procedures, either 
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PTCA (8.1% vs. 6.9%) or CABG (14.2% vs. 11.6%) (all, p<0.001).  On admission, 
diabetics were almost twice as likely to have renal dysfunction as measured by a serum 
creatinine greater than 2.5mg/dL or BUN greater than 40mg/dL level (13.7% vs. 7.5%, 
p<0.001).  Diabetics were more likely to present with an admission albumin level less 
than 3g/dL (5.5% vs. 4.3%), hematocrit less than 30 (5.8% vs. 4.5%), and a prothrombin 
time greater than 16 seconds (6.0% vs. 5.3%) (all, p<0.001).  Diabetics were also more 
likely to have on admission a left bundle branch block (7.2% vs. 5.4%, p<0.001) and a 
left ventricular ejection fraction less than 0.35 (18.3% vs. 14.3%, p<0.001), indicating 
poorer cardiac status.  However, diabetics were less likely to have creatine kinase levels 
greater than 4 times the normal level (28.4% vs. 32.3%, p<0.001).   
In terms of hospital procedure and course, diabetics were less likely to undergo 
PTCA (11.9% vs. 15.7%, p<0.001).  Mean length of stay was slightly longer for diabetic 
patients (7.38 days ± 5.0 vs. 6.82 days ± 4.7, p<0.001).  Diabetics were as likely to be 
discharged home as non-diabetics (61.1% vs. 62.8%, p=0.480).  However, those 
discharged to a long-term care facility were more likely to be diabetic (8.4% vs. 7.8%, 
p<0.001).  Patients who died during initial hospitalization were also more likely to be 
diabetic (12.2% vs. 10.2%, p<0.001). 
 
Medications During Admission and at Discharge 
 On admission, diabetics were less likely to be prescribed aspirin (83.0% vs. 
85.6%, p<0.001), beta blockers (50.3% vs. 56.3%, p<0.001), or thrombolytic therapy 
(49.8% vs. 63.2%, p<0.001).  At discharge, 63% of diabetics were on some form of 
diabetic medications (26.2% were on insulin therapy and 36.5% were prescribed oral 
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4hypoglycemics, including sulfonylureas/biguanides : data not shown).  Although not the 
standard of care during 1994-1995, nonetheless, statin therapy was prescribed equally to 
both diabetics and non-diabetics (4.5% vs. 4.6%, p=0.582)5.  As depicted in Figure 7, 
among ideal candidates at discharge, diabetics were less likely to be prescribed aspirin 
(63.8% vs. 69.0%, p<0.001) and beta-blocker therapy (36.3% vs. 42.0%, p<0.001), 
























Figure 7: Percent of Diabetic vs. Non-Diabetic Patients Receiving Evidence-Based 
Medications at Discharge (Among Ideal Candidates)  
10-Year Mortality 
Our primary analysis revealed a difference in mortality rates between diabetics 
and non-diabetics throughout the entire 10-year period (Figure 8).  In-hospital deaths (i.e. 
at time of initial hospitalization for AMI) were 12%.  Overall mortality for the study 
sample at 10 years was 69.4%.  Compared to non-diabetics, the overall unadjusted 10-
year mortality for diabetics was higher (77.2% vs. 65.4%).  We constructed multivariate 
                                                 
4 The most prescribed sulfonylurea was glipizide.  The only prescribed biguanide was metformin.  Because 
of the relatively small numbers of patients on biguanide therapy, we combined sulfonylureas and 
biguanides in subsequent analyses.  Only 1 patient was on glucosidase inhibitors and thus this class of 
medication was not included in any analyses. 
5 The most prescribed statin was lovastatin. 
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models using Cox proportional regression to estimate the overall 10-year mortality risk 
for diabetics and to adjust for confounders (Table 6).  In the unadjusted model we 
constructed, diabetics had higher 10-year mortality rates as compared to non-diabetics 
(HR=1.38, 95% CI: 1.37-1.40).  After addition of demographic and clinical 
characteristics to the unadjusted models, the hazard ratio was 1.30 (95% CI: 1.28-1.31).  
After adjusting for demographics, past medical history, procedures during hospitalization, 




  Figure 8: Differences in Survival Between Diabetics and Non-Diabetics Post-MI  




Table 6:  10-Year Mortality   
Unadjusted HR  95% CI 
Non-diabetics 1.00 -- 
1.38 Diabetics (1.37-1.40)  
Adjusted for Demographics & Clinical Variables  
Non-diabetics  1.00 -- 
Diabetics 1.30 (1.28-1.31) 
Adjusted for Demographics, Clinical Variables, & Quality of Care Indicators  Non-diabetics 1.00 -- 
1.29 Diabetics (1.27-1.31) 
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As part of our secondary analyses, we also examined mortality differences 
between patients who were prescribed statin therapy at discharge and those who were not 
prescribed statins.  The overall 10-year mortality for the statin group was lower compared 
to those not prescribed statin therapy (54.7% vs. 70.1%).  Among the group not 
prescribed statin therapy, diabetics had a higher mortality rate compared to non-diabetics 
(77.7% vs. 66.3%).  Interestingly as noted above, although there were no statistically 
significant differences in prescription rates of statin therapy for diabetics vs. non-
diabetics (4.5% vs. 4.6%, p<0.001), we found that the overall 10-year mortality rates for 
diabetics on statin therapy was higher as compared to non-diabetics on statins (67.7% vs. 
48.1%, p<0.001; Figure 9).   
  
We further restricted our analysis to diabetic patients only in order to analyze the 
effect of statin therapy on this cohort.  Among diabetic patients those on statin therapy 
had lower 10-year mortality than those not prescribed statin therapy (67.7% vs. 77.7%, 
Figure 10).   
Figure 9: Differences in Survival Between Diabetics on Statin Therapy and 
Non-Diabetics on Statin Therapy Post-MI (10 Year Data-Unadjusted) 
Non-Diabetic on statin therapy 
Diabetic on statin therapy 
 
  










Figure 10: Differences in Survival Between Diabetics on Statin Therapy and Diabetics  
not on Statin Therapy Post-MI (10 Year Data-Unadjusted) 
Diabetic on Statin Therapy  
Diabetic not on Statin Therapy  
We conducted further analyses with respect to diabetic related medications.  
Similarly, diabetic patients on oral medications (sulfonylureas and biguanides) had better 
10-year mortality outcomes compared to diabetic patients not on oral hypoglycemics 
(Figure 11).  However when restricting our analysis to insulin therapy, our Kaplan-Meier 
survival curves crossed between three and four years post-MI (Figure 12) suggesting non-
proportionality.  In our subsequent multivariate analysis as depicted below, mortality 
outcomes between diabetics and non-diabetics were analyzed from admission to three 
years and from four years to ten years post-MI.  Table 7 depicts unadjusted mortality 
rates for years 1-5 and at 10 years for diabetic patients on insulin and those not on insulin 
at discharge confirming our Kaplan-Meier findings. 
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Diabetic on Sulfyonlureas/Biguanides 
Diabetic not on Sulfyonlureas/Biguanides 
 
Figure 11: Differences in Survival Between Diabetics on Sulfonylurea/Biguanide 
Therapy and Diabetics not on Sulfonylurea/Biguanide Therapy Post-MI (10 Year 
Data-Unadjusted) 
 
Diabetic on Insulin 
Diabetic on Insulin 
Diabetic not on Insulin 
 
 
Figure 12: Differences in Survival Between Diabetics on Insulin Therapy and 
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Table 7:  Unadjusted Mortality for Diabetic Patients Receiving  Insulin 
therapy Post-MI: Years 1-5 & 10 
                                                     Mortality Rate  
Year Post-MI On Insulin Therapy Not On Insulin Therapy P 
35% 1 27% <0.001 
44% 2 39% <0.001 
50% 3 48% 0.008 
57% 4 56% 0.027 
64% 5 61% <0.001 
80% 10 77% <0.001 
 
Medication Use and Mortality Among Diabetics: Multivariate Analysis  
We also constructed a diabetic risk-adjusted model, limiting our analysis to 
diabetic patients.  In particular, we were interested in analyzing the relationship between 
medication use (insulin, sulfonylureas/biguanides, and statins) and long-term mortality 
(Table 8).  We analyzed the data in two time periods: 1) time from hospital admission to 
3 years (includes in-hospital related deaths); and 2) time from year 4-year 10 (excludes 
in-hospital related deaths).  Our choice of these time periods are fully described in the 
introduction.  For this analysis, we adjusted for demographics, clinical characteristics, 
medications on admission/discharge, and quality of care indicators. 
As depicted in Table 8, statin use at both time periods was associated with 
decreased mortality among diabetics.  During the first three years, in the unadjusted 
model, the hazard ratio for use of statin therapy was 0.58 (95% CI: 0.54-0.62).  With full 
adjustment this protective effect was reduced to 0.73 (95% CI: 0.69-0.78).  During the 
second time period, the unadjusted hazard ratio was 0.90 (95% CI: 0.84-0.95).  However, 
once we adjusted for demographics, clinical characteristics, and quality of care, statin use 
was no longer associated with a decrease in mortality (HR=0.95, 95% CI: 0.90-1.05).  
Similarly in our unadjusted models, both insulin use and sulfonylureas/biguanides were 
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associated with decreased mortality among diabetics during the first three years post-MI 
(HR for insulin=0.75, 95% CI: 0.73-0.77; HR for sulfonylureas/biguanides=0.55, 95% 
CI: 0.54-0.57).  This association remained even after full adjustment for demographics, 
clinical characteristics, and quality of care (HR for insulin=0.73, 95% CI: 0.71-0.75; HR 
for sulfonylureas/biguanides=0.63, 95% CI: 0.62-0.65).  However, analysis of our second 
time period revealed that both insulin and sulfonylureas/biguanides were associated with 
increased mortality among diabetics during years 4 through 10.  In our fully adjusted 
model, the hazard rate for sulfonylureas/biguanides use was 1.11 (95% CI: 1.08-1.15) 
while the hazard rate for insulin use was 1.30 (95% CI: 1.25-1.35).  Of patients on 
sulfonylureas/biguanides, 7.9% were also on insulin therapy and thus we observed an 
interaction between insulin and sulfonylureas/biguanides (data not shown). 
 
Table 8: Sequential Multivariate Cox Proportional Hazards 
Models Evaluating Medication Use (Insulin; Sulfonylureas & 
Biguanides; Statins) and Mortality in Diabetics During 2 Time 
Periods: Years 0-3 & Years 4-10 
     
Years 0-3* Years 4-10 Model Hazard Ratio 95% CI Hazard Ratio 95% CI 
1. Unadjusted     
   Insulin 0.75 0.73-0.77 1.31 1.26-1.35
   Sulf/Big 0.55 0.54-0.57 1.05 1.02-1.09
   Statins 0.58 0.54-0.62 0.90 0.84-0.95
2. Adjusted for Demographics    
   Insulin 0.78 0.76-0.80 1.39 1.34-1.44
   Sulf/Big 0.55 0.54-0.57 1.06 1.02-1.09
   Statins 0.66 0.62-0.70 0.98 0.92-1.05
3. Adjusted for Demographics, Clinical Variables, & Quality of Care  
   Insulin 0.73 0.71-0.75 1.30 1.25-1.35
   Sulf/Big 0.63 0.62-0.65 1.11 1.08-1.15
   Statins 0.73 0.69-0.78 0.95 0.90-1.02
     
*Includes in-hospital deaths=12%   
Sulf/Big=Sulfonylureas/Biguanides   
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VI. Discussion 
The principal finding of our study is that 10-year mortality for diabetics is higher 
than for non-diabetics.  Our study is unique because we showed that after full adjustment 
for demographics, clinical variables, and quality of care indicators, diabetics still had a 
29% increase in mortality compared to non-diabetics.  Our results are consistent with 
previous studies which demonstrate that diabetics have increased mortality after 
myocardial infarction (20, 22, 24, 47, 71-73).  Our results extend these findings because 
we had long-term follow-up data and we were also able to adjust for differences in 
quality of care among the two groups.  Our findings suggest that neither patient 
characteristics nor quality of care fully account for the poor outcomes among diabetics, 
suggesting that metabolic risk factors associated with diabetes ultimately require 
therapies beyond those currently recommended for post-MI patients. 
The aims of this study were: 1) to measure and compare 10-year mortality rates 
for diabetic and non-diabetic patients hospitalized with AMI; 2) to measure compliance 
rates with established guidelines in place during 1994-1995 regarding cardiac 
medications as a secondary prevention strategy among diabetic and non-diabetic patients 
hospitalized with AMI; and 3) to investigate the role of statin and diabetic therapies 
(insulin/oral hypoglycemics) in decreasing 3 and 10-year mortality rates for diabetics 
hospitalized with AMI.  With regards to our aim of measuring compliance rates with 
established guidelines regarding cardiac medications as a secondary prevention strategy 
among diabetic and non-diabetic patients hospitalized with AMI, we found that aspirin 
was not prescribed to 35.5% of diabetics who were ideal candidates for the therapy.  
Among this group of ideal candidates, beta-blockers were also not prescribed to 63.4% of 
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diabetics eligible for the therapy.  Equally surprising was that overall use of aspirin and 
beta-blocker therapy at discharge was also low for non-diabetics eligible to receive them.  
Less than 70% of non-diabetics were prescribed aspirin at discharge and less than 50% of 
non-diabetics eligible for beta-blockers were prescribed the medication at discharge.  Our 
results are consistent with other studies that have demonstrated that diabetics are less 
likely to receive evidence-based care post-MI (21, 23, 24, 47, 48, 56).  The strength of 
our study was not only in validating the results of other investigators but we believe our 
study was able to extend these findings because we limited our analysis to ideal 
candidates.  We believe that our study is valuable for it is in line with the original primary 
aims of the CCP initiative: to describe quality of care practices among ideal candidates 
hospitalized with AMI.  Our results suggest that there is opportunity for improvement in 
management of diabetics post-MI since our data confirms that diabetics receive 
suboptimal medical care. 
Underutilization of both aspirin and beta-blockers is surprising since both 
therapies are a proven and effective secondary prevention strategy for patients post-MI.  
Additionally, at the start of our study in 1994, ACC/AHA guidelines recommended use 
of both therapies as secondary prevention strategies for patients post-MI.  A meta-
analysis of more than 18,000 patients enrolled in randomized controlled trials through 
March 1990 demonstrated that antiplatelet therapy reduced long-term mortality in both 
diabetic and non-diabetic patients (74).  As noted in the introduction, a possible 
explanation as to why aspirin and beta-blockers may have been underutilized in diabetic 
patients is due to the controversies surrounding both therapies at the initiation of our 
study.  The 1990 ACC/AHA guidelines suggested caution when prescribing beta-blocker 
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therapy for insulin-dependent diabetics most likely due to the theory that hypoglycemic 
symptoms would be masked as a result of the blunting of reflex tachycardia by beta-
blocker therapy.  However, this would not explain why non-diabetics were also not 
receiving this important therapy.  With regards to aspirin therapy, although the results of 
the ETDRS in 1992 showed that aspirin did not increase the risk of ocular hemorrhage, 
ADA practice guidelines did not recommend aspirin for diabetics until 1997.  This may 
have been due to an additional concern regarding a possible interaction between aspirin 
and ACE-Is in terms of renal function (75, 76).  One study showed that among patients 
with severe CHF, aspirin therapy attenuated the vasodilator effects of the ACE-I enalapril 
(77).  A subgroup analysis of the Cooperative New Scandinavian Enalapril Survival 
Study II (CONSENSUS II) demonstrated a negative interaction between enalapril and 
aspirin and that this interaction was a predictor of mortality (p=0.047).  Interestingly, our 
study showed that among ideal candidates diabetics were more likely to be prescribed 
ACE-Is as compared to non-diabetics (61% vs. 55% p<0.001).  This may suggest that 
physicians were indeed concerned about a possible adverse interaction between ACE-Is 
and aspirin and thus chose one therapy over the other.  Both Norhammar et al. and 
Vaccarino et al. in their respective studies also have demonstrated that compared to non-
diabetics, diabetics are more likely to be prescribed ACE-Is as opposed to aspirin or beta-
blockers (21, 47).  However, none of the authors proposed an explanation for this finding.  
Additionally, unlike our study, their analyses were not restricted to ideal candidates and 
thus their cohort may have been comprised of diabetics with nephropathy requiring the 
use of ACE-Is.   
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While it is important to acknowledge the controversies that existed during the 
time of our study which may have contributed to the decreased prescription of therapies 
among diabetics, our findings that among ideal candidates even non-diabetics were 
receiving suboptimal care suggest that physicians’ adherence to guidelines is less than 
ideal.  As noted previously, evidence exists from several studies that there is 
underutilization of evidence-based therapies among the elderly in general (10, 46, 49-56, 
78-81).  Consequently, this was the impetus behind the creation of the CCP.  Although 
great strides have been undertaken to improve quality of care for the elderly and diabetics 
over the past decade, recent studies show that there are still significant disparities in 
healthcare especially for diabetics (82, 83).  Grant et al. in a retrospective cohort study of 
1,765 diabetic patients conducted from 2000-2002 in 30 US academic medical centers 
demonstrated that physicians did not make appropriate medication adjustments to meet 
practice guideline goals such as HbA1c levels less than 7%, blood pressure less than 
130/80 mmHg, or lipid goals less than 100 mg/dL (84) suggesting that greater 
improvements are needed in this area. 
 In order to acknowledge paradigm shifts in medical care that may have 
unknowingly influenced results from our study, we analyzed our data in two time periods 
and further restricted our analysis to diabetics only.  Unfortunately, because this is a 
retrospective study, it is difficult to determine with certainty to what extent if any our 
data is subject to a period effect.  We were concerned given the controversies that existed 
with regards to medical therapy that there were systematic differences between groups 
that would have influenced our data.  For example, because of the national scope of our 
data, academic centers, where many of these landmark studies originated, may have 
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treated diabetics more aggressively even before practice guidelines officially changed as 
opposed to community hospitals.  We tried to limit this by controlling for hospital 
characteristics and adjusting for clustering among hospitals but there may be additional 
unknown confounders for which we did not adjust.  We did not apply further regression 
techniques to explore this issue and is a limitation of our study. 
 Surprisingly, the analysis of our data in two time periods revealed an interesting 
relationship between insulin therapy and mortality within the diabetic cohort.  Within the 
first three years, in our fully adjusted model, insulin therapy was associated with 
decreased mortality (HR=0.73, 95% CI: 0.71-0.75) whereas in the remaining seven years, 
it was associated with increased mortality (HR=1.30, 95% CI: 1.25-1.35).  The same was 
true for sulfonylurea/biguanide therapy (HR years 0-3=0.63, 95% CI: 0.62-0.65; HR 
years 4-10=1.11, 95% CI: 0.71-0.75).  Berger et al. also found an increased risk of 
mortality with insulin use while a study by Chyun et al. did not find this association (22, 
24).  It is important to note that both authors used data from the CCP but only analyzed 
short-term mortality.  The study by Berger et al. was national in scope whereas the study 
by Chyun et al. was limited to Connecticut.  Although our data revealed an increase in 
mortality after the third year while Berger et al. found this association at one year, we 
agree with the conclusions of Berger et al. and believe this most likely represents 
confounding and that this association represents increasing disease burden among 
diabetics as time progresses.  In other words, insulin may just be a marker of disease 
progression.  We cannot draw any firm conclusions because we did not have information 
on medication dosages so we cannot fully correlate medication with outcomes.  We 
cannot determine if those who reaped a benefit in the first three years were on high or 
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low dosages of insulin, whether they had just been started on therapy during initial 
hospitalization for AMI, or what their admission glucose levels/HbA1c were.  It is known 
that stress hyperglycemia at the time of initial MI can increase the risk of death.  A recent 
meta-analysis described that non-diabetics who had glucose concentrations between 6.1-
8.0 mmol/L had a 3.9 increased risk of mortality (95% CI: 2.9-5.4) as compared to non-
diabetics with lower glucose concentrations.  Higher range of glucose concentrations 
(8.0-10.0 mmol/L) increased the risk of CHF or cardiogenic shock.  Among diabetic 
patients those with glucose concentrations between 10-11.0 mmol/L had a 1.7 increased 
risk of mortality (95% CI: 1.2-2.4) (85).   
An alternative, but admittedly less likely explanation for our finding is that this 
may represent “metabolic memory” similar to the recent findings of the Epidemiology of 
Diabetes Intervention and Complications (EDIC) study, an 11-year follow-up of DCCT 
participants.  The EDIC study showed that CVD events were reduced years after 
intensive insulin therapy among type 1 diabetics had ended in the original randomized 
controlled trial (86).  However, unlike our study this was a randomized controlled trial in 
type 1 diabetics who had undergone years of intensive insulin therapy.  It is highly 
unlikely that patients received an intensive insulin regimen during hospitalization and if 
they did, as mentioned previously, we do not have information regarding medication 
dosages to determine the effect.  Additionally, we do not have information regarding type 
of diabetes or duration of disease.  Thus, without information regarding type of diabetes, 
duration of disease, medication dosages, and glycemic-related admission characteristics, 
we cannot analyze this finding further or make any firm conclusions.  How intensive 
insulin therapy affects CVD and long-term outcomes will most likely be answered by 
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several ongoing randomized controlled trials such as the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study, results for which are expected in 
2009. 
 Similarly our findings for sulfonylureas are difficult to interpret.  We were 
surprised to find that while our unadjusted Kaplan-Meier curve did not indicate a cross-
over in mortality between years 3 and 4, our Cox regression models did.  As indicated 
previously, a proportion of patients on sulfonylureas were also on insulin therapy.  Our 
findings most likely suggest an interaction between these therapies, however we were not 
able to evaluate this further and is a limitation of our study.  Additionally, there has been 
conflicting information regarding the effect of sulfonylureas and CVD mortality.  
Because sulfonylureas close potassium channels, it has been hypothesized that closure of 
these channels in cardiac cells impairs ischemic preconditioning, which normally allows 
cardiac cells to survive during periods of ischemia (87).  Another theory is that 
sulfonylurea toxicity is pro-arrhythmic (87).  The University Group Diabetes Project 
(UGDP) study demonstrated that those treated with the sulfonylurea agent, tolbutamide, 
had higher cardiovascular-related deaths than those on placebo whereas results from the 
UKPDS showed that sulfonylurea therapy with glyburide did not increase risk of death 
(88, 89).  A recent meta-analysis demonstrated that a dose-response relationship exists 
among first generation sulfonylureas and glyburide therapy and mortality among type 2 
diabetics (87).  It should be noted that in our study the most prescribed sulfonylurea was 
glipizide which was not specifically studied in this meta-analysis but both glyburide and 
tolbutamide were also used by patients in our cohort.  Again, because we did not abstract 
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information on medication dosages, we cannot adequately evaluate the relationship 
between sulfonylureas and mortality. 
 In contrast, we demonstrated that statin therapy was mostly associated with 
decreased mortality over the 10-year time period (HR years 0-3 fully adjusted 
model=0.73, 95% CI: 0.69-0.78; HR years 4-10 fully adjusted model=0.95, 95% CI: 
0.90-1.02).  Statin therapy is now the mainstay of cardiac therapy and thus it is not 
surprising that as numerous studies such as the Scandinavian Simvastatin Survival Study 
Group (4S), the Cholesterol and Recurrent Events (CARE) trial, and the Long-Term 
Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group have 
demonstrated, statin therapy decreases mortality even among diabetics (90-93).   
 
Strengths and Limitations 
 Our study was subject to several limitations.  First, because this is a retrospective 
study it is subject to limitations inherent to such a design.  The data used in this study is 
only reflective of what was documented in patients’ charts.  Certain therapies may not 
have been recorded.  Errors in medical abstraction could have also occurred, especially in 
the identification of ideal candidates, leading to misclassification.  This misclassification 
is most likely non-differential and would bias our results toward the null.  Medical record 
abstraction is difficult because charts may sometimes be illegible, poorly organized, and 
because charts are written as narratives rather than standardized forms, the ability to 
abstract the necessary data may be challenging (10, 55).  Although validation studies of 
the CCP have documented high reliability of the data abstracted (7), the data is not 
perfect.  Lastly, because we excluded transferred patients we may have introduced a 
selection bias.  
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As compared to randomized controlled trials, observational studies are often 
subject to uncontrolled confounding.  Because we only abstracted clinical data regarding 
cardiac and diabetic medications we cannot account for use of other medications either 
physician prescribed or over-the-counter medications (i.e. vitamins), that may have 
affected our analysis.  For example, we do not have information on the percentage of 
women in the cohort who may have been taking hormone replacement therapy (HRT) 
which at the time of our study was thought to decrease the risk of coronary events (94).  
This is an important confounder because after the initiation of our study, results from the 
Women’s Health Initiative in 2003 showed that HRT increases cardiovascular-related 
mortality (95).  Other important confounders to consider are socioeconomic status, 
education, and lifestyle characteristics such as exercise, including cardiac rehabilitation 
post-MI, and diet. 
Most importantly, the CCP was not originally designed to assess diabetic 
outcomes.  As mentioned previously, we did not distinguish between the different types 
of diabetes in our sample.  Also, we did not have information regarding duration of 
disease or several important admission characteristics such as body mass index, glycemic 
variables (i.e. HbA1c levels or fasting plasma glucose levels), lipid levels, or medication 
dosages.  Because diabetic status was not confirmed via measurement of HbA1c levels or 
fasting plasma glucose levels, we may have underestimated the prevalence of diabetes, 
potentially resulting in disease misclassification.  Again, this most likely represents non-
differential disease misclassification biasing our results towards the null. It should be 
noted that statin therapy was not part of the standard of care during this time period and 
no quality of care indicators were developed for this therapy.  We were unable to 
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correlate cholesterol levels on admission with statin therapy and we could not reliably 
determine what the independent effect of statin use in this cohort had on long-term 
mortality.  However, although it was not the standard of care during this time period, 
statin therapy was prescribed equally to both diabetics and non-diabetics (4.5% vs. 4.6%, 
p=0.582).  Furthermore, among those treated with evidence-based therapies, we do not 
know whether patients were treated to target levels so we cannot reliably determine the 
effect this had on mortality.  With regards to our primary outcome, mortality, we did not 
analyze cardiovascular-related mortality but rather all-cause mortality.  Lastly, practice 
guidelines for the care of patients with AMI along with diabetic management have 
changed considerably.  Thus, caution should be employed when trying to generalize these 
findings to a contemporary cohort. 
Although we acknowledge these limitations, we believe our study has several 
strengths.  The CCP is a well-known, large cohort that has been validated and provides a 
comprehensive picture of the quality of care of elderly patients hospitalized with AMI.  
Numerous published studies have used data from the CCP to describe treatment practices 
for patients with AMI and describe changes over time with regards to the quality of care 
patients hospitalized with AMI have received (10, 22, 24, 47, 51, 52, 55, 57).  However, 
data regarding diabetic patients in this cohort have been minimal especially with regards 
to long-term follow-up.  This is the first time that 10-year mortality data from the CCP 
cohort looking at diabetic mortality has been presented.6  We limited our mortality 
analysis to patients who were ideal candidates for these therapies.  Therefore, we were 
able to examine the impact quality of care had on long-term mortality outcomes.  
                                                 
6 We presented an abstract of some of our initial findings at both the ADA Scientific Sessions (San Diego, 
California, June 2005) and the AHA Scientific Sessions (Dallas, Texas, November 2005). 
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Because the CCP utilizes cases from the Medicare databases, we were able to decrease 
selection bias that may result from randomized trials.  Use of Medicare data also 
eliminates the ability to pay for care as a confounder in our study.  While we recognize 
practice guidelines have changed considerably, it has also been noted that practice 
guidelines are slow to disseminate and thus the patterns we observed in our study with 
regards to treatment and procedure use may in fact be reflective of care patients received 
several years post 1994-1995 (81, 96, 97). 
 
Conclusion 
The impetus behind this thesis was to determine reasons behind the observed 
increased mortality diabetics face post-MI and to determine how quality of care impacts 
long-term outcomes for this group.  As discussed, several authors have attempted to 
characterize whether this increased short-term mortality is due to biological differences 
or whether this increased mortality is due to health disparities-namely a difference in the 
quality of care diabetics receive post-MI.  Additionally, few studies have specifically 
examined long-term mortality for diabetics post-MI.  Our findings that both non-diabetics 
and diabetics were less likely to receive evidence-based therapies post-MI suggest that 
we need to encourage physicians to adopt and better implement evidence-based 
guidelines especially for those historically most vulnerable to disparities in healthcare: 
the elderly and diabetics.  As the number of diabetics increase worldwide and as the 
population ages, elderly diabetics will be the group most in need of new and effective 
strategies in order to successfully combat their diseases and decrease their mortality.  As 
recently demonstrated by Eagle et al., the implementation of guideline-based AMI 
standard care is associated with improved 30-day and 1-year mortality within a Medicare 
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cohort post-MI (98).  By extension, we believe that implementing guideline-based AMI 
standard care can likely improve long-term outcomes as well.  However, our findings 
also suggest that even after accounting for quality of care, diabetics still have a 
substantial increase in long-term mortality.  While our study is one of the first to 
highlight long-term mortality outcomes for elderly diabetics, more research is clearly 
needed in this field.  For example, future studies examining sex-based differences with 
regards to long-term mortality for elderly diabetics will be valuable.  Studies also 
examining cardiovascular-related mortality will be extremely informative.  We believe 
that in order for this research to be successful, it will require a collaboration between 
basic scientists, clinicians, and epidemiologists to identify and address both the 
underlying metabolic factors and disparities in quality of care that clearly place elderly 
diabetics at greatest risk of mortality post-MI.   
  





 A1. Estimated Prevalence of Diabetes Worldwide: Year 2000 and 2030.  Source: 
World Health Organization (4)  
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A2. Estimated Prevalence of 
Diabetes by Age Group 
(Developed vs. Developing 
Countries): Year 2000 and 
2030.  Source: World Health 
Organization (2) 
    
 
                
A3. Incidence of Myocardial 
Infarction in Diabetics and 
Non-Diabetics with and 
without prior MI.  Source: 
“Diabetes and Cardiovascular 







  52 
VIII. References 
1. MacKay J, Mensah G. The Atlas of Heart Disease and Stroke. Geneva: World 
Health Organization; 2004. 
2. Number of Adults with Diabetes in Developed and Developing Countries. 
(Accessed February 10, 2006, 2006, at 
http://www.who.int/diabetes/actionnow/en/diabprev.pdf.) 
3. World Health Organization. Preventing Chronic Diseases a Vital Investment. 
Geneva: World Health Organization,; 2005. 
4. Prevalence of Diabetes World Map. (Accessed February 10, 2006, 2006, at 
http://www.who.int/diabetes/actionnow/en/mapdiabprev.pdf.) 
5. Cardiovascular Disease Conditions Among Adults with Diabetes Aged 35 Years 
and Older. 2005. (Accessed February 10, 2006, 2006, at 
http://www.cdc.gov/diabetes/statistics/cvd/index.htm.) 
6. International Diabetes Federation. Diabetes and Cardiovascular Disease: Time 
to Act. Brussels: International Diabetes Federation; 2001. 
7. Huff ED. Comprehensive reliability assessment and comparison of quality 
indicators and their components. J Clin Epidemiol 1997;50(12):1395-404. 
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: 
estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-
53. 
9. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. 
Dallas: American Heart Association; 2005. 
10. Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of 
care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare 
health care quality improvement program. Arch Intern Med 2003;163(12):1430-9. 
11. Older Americans and Cardiovascular Diseases-Statistics. American Heart 
Association, 2004. (Accessed at 
http://www.americanheart.org/downloadable/heart/1136584495498OlderAm06.pdf.) 
12. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: 
a statement for healthcare professionals from the American Heart Association. 
Circulation 1999;100(10):1134-46. 
13. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to 
diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28(9):2130-5. 
14. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the 
Framingham study. Circulation 1979;59(1):8-13. 
15. McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J 
1999;138(5 Pt 1):S366-75. 
16. Bonow ROMDC, Mitch WEMD, Nesto RWMD, et al. Prevention Conference VI: 
Diabetes and Cardiovascular Disease: Writing Group V: Management of 
Cardiovascular-Renal Complications. Prevention Conference VI: Diabetes and 
Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare 
Professionals From a Special Writing Group of the American Heart Association. 
Circulation May 7 2002;105(18):e159-e64. 
17. Moser M, Sowers JR. Clinical Management of Cardiovascular Risk Factors in 
Diabetes. 1st Edition ed. Caddo: Professional Communications, Inc.; 2002. 
  
  53 
18. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and 
outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 
1997;126(4):296-306. 
19. Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. 
Increased congestive heart failure after myocardial infarction of modest extent in 
patients with diabetes mellitus. Am Heart J 1984;108(1):31-7. 
20. Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction 
in diabetic and non-diabetic patients. Diabet Med 1993;10(5):449-54. 
21. Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L. 
Under utilisation of evidence-based treatment partially explains for the unfavourable 
prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 
2003;24(9):838-44. 
22. Chyun D, Vaccarino V, Murillo J, Young LH, Krumholz HM. Cardiac outcomes 
after myocardial infarction in elderly patients with diabetes mellitus. Am J Crit Care 
2002;11(6):504-19. 
23. Lim LL, Tesfay GM, Heller RF. Management of patients with diabetes after heart 
attack: a population-based study of 1982 patients from a heart disease register. Aust N Z 
J Med 1998;28(3):334-42. 
24. Berger AK, Breall JA, Gersh BJ, et al. Effect of diabetes mellitus and insulin use 
on survival after acute myocardial infarction in the elderly (the Cooperative 
Cardiovascular Project). Am J Cardiol 2001;87(3):272-7. 
25. Spector KS. Diabetic cardiomyopathy. Clin Cardiol 1998;21(12):885-7. 
26. Mahgoub MA, Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell 
Biochem 1998;180(1-2):59-64. 
27. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of 
hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 
1990;82(3):848-55. 
28. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary 
atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. 
Diabetologia 2000;43(5):632-41. 
29. Pajunen P, Taskinen MR, Nieminen MS, Syvanne M. Angiographic severity and 
extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol 
2000;86(10):1080-5. 
30. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at 
necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic 
patients with and without clinical evidence of coronary heart disease and comparison to 
183 control subjects. Am J Med 1980;69(4):498-506. 
31. Burchfiel CM, Reed DM, Marcus EB, Strong JP, Hayashi T. Association of 
diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study 
from the Honolulu Heart Program. Am J Epidemiol 1993;137(12):1328-40. 
32. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from 
coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with 
and without prior myocardial infarction. N Engl J Med 1998;339(4):229-34. 
33. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in 
non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study 
(UKPDS: 23). BMJ 1998;316(7134):823-8. 
  
  54 
34. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent 
risk factor for ischemic heart disease. N Engl J Med 1996;334(15):952-7. 
35. Zareba W, Pancio G, Moss AJ, et al. Increased level of von Willebrand factor is 
significantly and independently associated with diabetes in postinfarction patients. 
THROMBO Investigators. Thromb Haemost 2001;86(3):791-9. 
36. Johnstone M, Creager S, Scales K, Cusco J, Lee B, Creager M. Impaired 
endothelium-dependent vasodilation in patients with insulin- dependent diabetes mellitus. 
Circulation 1993;88(6):2510-6. 
37. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with 
macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): 
prospective observational study. BMJ 2000;321(7258):405-12. 
38. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk 
Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 
Diabetes: UKPDS 66. Diabetes Care 2004;27(1):201-7. 
39. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in 
tissue and the biochemical basis of diabetic complications. N Engl J Med 
1988;318(20):1315-21. 
40. Pathophysiology of Heart Disease. Baltimore: Lippincott Williams & Wilkins; 
1998. 
41. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: 
a new factor of the metabolic syndrome. A population-based study. Diabetes Care 
1998;21(4):649-54. 
42. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. 
Plasminogen activator inhibitor-1 activity is independently related to both insulin 
sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol 
1998;18(2):258-64. 
43. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet 
function in type II diabetes mellitus. N Engl J Med 1990;322(25):1769-74. 
44. DiMinno G, Silver MJ, Cerbone AM, et al. Increased binding of fibrinogen to 
platelets in diabetes: the role of prostaglandins and thromboxane. Blood 
1985;65(1):156-62. 
45. Younis N, Burnham P, Patwala A, Weston PJ, Vora JP. Beta blocker prescribing 
differences in patients with and without diabetes following a first myocardial infarction. 
Diabetic Medicine 2001;18(2):159-61. 
46. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention 
after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern 
Med 1996;124(3):292-8. 
47. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Impact of history 
of diabetes mellitus on hospital mortality in men and women with first acute myocardial 
infarction. The National Registry of Myocardial Infarction 2 Participants. Am J Cardiol 
2000;85(12):1486-9; A7. 
48. Chowdhury TA, Lasker SS, Dyer PH. Comparison of secondary prevention 
measures after myocardial infarction in subjects with and without diabetes mellitus. J 
Intern Med 1999;245(6):565-70. 
  
  55 
49. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the treatment of acute 
myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. 
Circulation 1995;92(10):2841-7. 
50. Krumholz HM, Murillo JE, Chen J, et al. Thrombolytic therapy for eligible 
elderly patients with acute myocardial infarction. Jama 1997;277(21):1683-8. 
51. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National 
use and effectiveness of beta-blockers for the treatment of elderly patients after acute 
myocardial infarction: National Cooperative Cardiovascular Project. Jama 
1998;280(7):623-9. 
52. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for 
Medicare patients with acute myocardial infarction: results from the Cooperative 
Cardiovascular Project. Jama 1998;279(17):1351-7. 
53. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients 
with acute myocardial infarction. A four-state pilot study from the Cooperative 
Cardiovascular Project. Jama 1995;273(19):1509-14. 
54. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national 
guidelines for drug treatment of suspected acute myocardial infarction: evidence for 
undertreatment in women and the elderly. Arch Intern Med 1996;156(7):799-805. 
55. O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the 
treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. Jama 
1999;281(7):627-33. 
56. Jackson EA, Sivasubramian R, Spencer FA, et al. Changes over time in the use of 
aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): a 
population-based perspective. Am Heart J 2002;144(2):259-68. 
57. Foody JM, Wang Y, Kiefe CI, et al. Long-term prognostic importance of total 
cholesterol in elderly survivors of an acute myocardial infarction: the Cooperative 
Cardiovascular Pilot Project. J Am Geriatr Soc 2003;51(7):930-6. 
58. Vaccarino V, Horwitz RI, Meehan TP, Petrillo MK, Radford MJ, Krumholz HM. 
Sex differences in mortality after myocardial infarction: evidence for a sex-age 
interaction. Arch Intern Med 1998;158(18):2054-62. 
59. Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the early 
management of patients with acute myocardial infarction. A report of the American 
College of Cardiology/American Heart Association Task Force on Assessment of 
Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop 
Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J 
Am Coll Cardiol 1990;16(2):249-92. 
60. Paty BW. Managing myocardial infarction in the diabetic patient. Endocrinol 
Metab Clin North Am 2000;29(4):831-42. 
61. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early 
Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. Jama 
1992;268(10):1292-300. 
62. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997;20(11):1767-71. 
63. Nattrass M. Managing diabetes after myocardial infarction. Bmj 
1997;314(7093):1497. 
  
  56 
64. The effect of intensive treatment of diabetes on the development and progression 
of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control 
and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86. 
65. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose 
infusion followed by subcutaneous insulin treatment in diabetic patients with acute 
myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 
1995;26(1):57-65. 
66. Malmberg K. Prospective randomised study of intensive insulin treatment on long 
term survival after acute myocardial infarction in patients with diabetes mellitus. 
DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) 
Study Group. Bmj 1997;314(7093):1512-5. 
67. Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom 
Prospective Diabetes Study. Lancet 1998;352(9131):832-3. 
68. Tight blood pressure control and risk of macrovascular and microvascular 
complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. 
Bmj 1998;317(7160):703-13. 
69. Enrollment Database Files. (Accessed February 10, 2006, 2006, at  
70. Stata Corporation. Statistics Data Management Graphics Reference G-0. College 
Station: Stata Corporation; 1997. 
71. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on 
survival following myocardial infarction in men vs women. The Framingham Study. Jama 
1988;260(23):3456-60. 
72. Donahue RP, Goldberg RJ, Chen Z, Gore JM, Alpert JS. The influence of sex and 
diabetes mellitus on survival following acute myocardial infarction: a community-wide 
perspective. J Clin Epidemiol 1993;46(3):245-52. 
73. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the 
first myocardial infarction. The FINMONICA Myocardial Infarction Register Study 
Group. Diabetes Care 1998;21(1):69-75. 
74. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention 
of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various 
categories of patients. Antiplatelet Trialists' Collaboration. Bmj 1994;308(6921):81-106. 
75. Dietz R, Nagel F, Osterziel KJ. Angiotensin-converting enzyme inhibitors and 
renal function in heart failure. Am J Cardiol 1992;70(10):119C-25C. 
76. Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K. Effects of 
acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med 
1991;90(5):571-5. 
77. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of 
enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20(7):1549-55. 
78. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices 
compared with practice guidelines: use of beta-blockade after acute myocardial 
infarction. J Am Coll Cardiol 1995;26(6):1432-6. 
79. Becker RC, Burns M, Gore JM, Lambrew C, French W, Rogers WJ. Early and 
pre-discharge aspirin administration among patients with acute myocardial infarction: 
current clinical practice and trends in the United States. J Thromb Thrombolysis 
2000;9(3):207-15. 
  
  57 
80. O'Rourke RA. Are beta-blockers really underutilized in postinfarction patients? J 
Am Coll Cardiol 1995;26(6):1437-9. 
81. Udvarhelyi IS, Gatsonis C, Epstein AM, Pashos CL, Newhouse JP, McNeil BJ. 
Acute myocardial infarction in the Medicare population. Process of care and clinical 
outcomes. Jama 1992;268(18):2530-6. 
82. Mitka M. Diabetes management remains suboptimal: even academic centers 
neglect curbing risk factors. Jama 2005;293(15):1845-6. 
83. Hirsch IB. The Burden of Diabetes (Care) 
Diabetes Care 2003;26(5):1613-4. 
84. Grant RW, Buse JB, Meigs JB, for the University HealthSystem Consortium  
Diabetes Benchmarking Project Team. Quality of Diabetes Care in U.S. Academic 
Medical Centers: Low rates of medical regimen change   
Diabetes Care 2005;28(2):337-442. 
85. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and 
increased risk of death after myocardial infarction in patients with and without diabetes: 
a systematic overview. Lancet 2000;355(9206):773-8. 
86. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and 
cardiovascular disease in patients with type 1 diabetes. N Engl J Med 
2005;353(25):2643-53. 
87. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response 
relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a 
population-based cohort study. Cmaj 2006;174(2):169-74. 
88. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of 
hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. 
Mortality results. Diabetes 1970;19:Suppl:789-830. 
89. Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes 
(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 
1998;352(9131):837-53. 
90. Randomised trial of cholesterol lowering in 4444 patients with coronary heart 
disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-
9. 
91. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary 
events after myocardial infarction in patients with average cholesterol levels. Cholesterol 
and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9. 
92. Prevention of cardiovascular events and death with pravastatin in patients with 
coronary heart disease and a broad range of initial cholesterol levels. The Long-Term 
Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 
1998;339(19):1349-57. 
93. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their 
reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction 
survivors with average cholesterol levels: subgroup analyses in the cholesterol and 
recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98(23):2513-9. 
94. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A 
prospective, observational study of postmenopausal hormone therapy and primary 
prevention of cardiovascular disease. Ann Intern Med 2000;133(12):933-41. 
  
  58 
95. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of 
coronary heart disease. N Engl J Med 2003;349(6):523-34. 
96. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. 
Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 
1992;327(4):248-54. 
97. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of 
results of meta-analyses of randomized control trials and recommendations of clinical 
experts. Treatments for myocardial infarction. Jama 1992;268(2):240-8. 
98. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is 
associated with substantially lower mortality in medicare patients with acute myocardial 
infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) 
Projects in Michigan. J Am Coll Cardiol 2005;46(7):1242-8. 
 
 
  
